Novavax, Inc. (NVAX) News
Filter NVAX News Items
NVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVAX News Highlights
- NVAX's 30 day story count now stands at 20.
- Over the past 17 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, BASE and FCF are the most mentioned tickers in articles about NVAX.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
1 Green Flag and 1 Red Flag for NovavaxNovavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals. |
Novavax (NVAX) Gains But Lags Market: What You Should KnowNovavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day. |
Is Novavax Stock A Sell After Expressing 'Substantial Doubt' About Its Future?Is Novavax stock a sell after the company says it has "substantial doubt" about its future? Is NVAX stock a sell right now? |
2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully SoOn that note, here are a couple of severely beaten-down growth stocks that are popular among investors, but only one of them has a credible path to stay in business. With ambitions to become the world's biggest seller of legal cannabis products, Tilray Brands (NASDAQ: TLRY) is also a growth stock that's remarkably inexpensive. Despite reporting $144 million in revenue for its fiscal second quarter and free cash flow (FCF) of $25.4 million, its shares are down 42.7% in the last three years because of persistent unprofitability and wild oversupply compared to demand across several continents. |
3 Vaccine Stocks to Watch for Their Post-Pandemic MovesThe vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. |
This Growth Stock Is Down 90%. Is It Time to Sell or Buy?In light of the pessimistic messaging from its management and the low expectations that professional analysts have for it over the next couple of years, shareholders now face the prospect of the company's potential collapse. The crux of Novavax's problem is that its coronavirus vaccines were approved too late to gain a significant share of the global market, which competitors like Pfizer and Moderna cornered quite rapidly thanks to favorable receptions from regulators and sufficient manufacturing capacity to meet demand on a reasonable timetable. Due to a series of mishaps with its manufacturing operations, Novavax's Nuvaxovid jab didn't get an Emergency Use Authorization (EUA) from the Food and Drug Administration until mid-July 2022 -- almost two years later than Pfizer's vaccine go... |
1 Stock You Need to Sell Before the Next Bull MarketDespite the long-lived loyalty of Novavax's (NASDAQ: NVAX) boisterous base of retail investors called the "Nova-stans," the company's seemingly endless struggles appear poised to burden it to the point of collapse. While it's faintly possible that the biotech will survive, investors shouldn't stick around to find out, and it's probably also time to do some soul-searching about the merits of deciding to become one of its shareholders in the first place. At the moment, Novavax has a gnarly complex of problems that it has no way of solving. |
Novavax Stock: Bear vs. BullNovavax (NASDAQ: NVAX) has a track record of major gains and major losses within the past few years. Novavax shares have dropped a mind-boggling 97% from their peak. Considering all of this, should you buy Novavax or avoid the stock? |
Novavax Just Dropped a Bombshell on Investors: Even Management Is Questioning Its FutureNovavax (NASDAQ: NVAX) faces an uncertain future ahead as the need for COVID-19 vaccines diminishes. The situation is so bad that even management issued a warning on its latest quarterly earnings report. Last month, Novavax released its year-end results. |
Novavax to Participate in TD Cowen's 43rd Annual Health Care ConferenceNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference. |